Boule Diagnostics AB (publ) (BOUL.ST)
SEK 8.84
(-1.56%)
SEK 8.84
(-1.56%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 166.1 Million SEK | -12.56% |
| 2022 | 189.96 Million SEK | 22.21% |
| 2021 | 155.44 Million SEK | 23.87% |
| 2020 | 125.48 Million SEK | -18.2% |
| 2019 | 153.4 Million SEK | 106.34% |
| 2018 | 74.34 Million SEK | 13.66% |
| 2017 | 65.41 Million SEK | 14.18% |
| 2016 | 57.29 Million SEK | -7.96% |
| 2015 | 62.24 Million SEK | 22.59% |
| 2014 | 50.77 Million SEK | 9.43% |
| 2013 | 46.39 Million SEK | 121.88% |
| 2012 | 20.91 Million SEK | -43.26% |
| 2011 | 36.85 Million SEK | 36.1% |
| 2010 | 27.08 Million SEK | 37.34% |
| 2009 | 19.71 Million SEK | -16.38% |
| 2008 | 23.58 Million SEK | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 178.4 Million SEK | 7.41% |
| 2024 Q3 | 163.9 Million SEK | -2.73% |
| 2024 Q2 | 183.3 Million SEK | 2.75% |
| 2023 Q2 | 184.7 Million SEK | 1.54% |
| 2023 FY | 166.1 Million SEK | -12.56% |
| 2023 Q4 | 166.1 Million SEK | -11.51% |
| 2023 Q3 | 187.7 Million SEK | 1.62% |
| 2023 Q1 | 181.9 Million SEK | -4.25% |
| 2022 Q3 | 245.2 Million SEK | 13.1% |
| 2022 Q1 | 174 Million SEK | 11.94% |
| 2022 Q4 | 189.96 Million SEK | -22.53% |
| 2022 FY | 189.96 Million SEK | 22.21% |
| 2022 Q2 | 216.8 Million SEK | 24.6% |
| 2021 Q4 | 155.44 Million SEK | 4.04% |
| 2021 FY | 155.44 Million SEK | 23.87% |
| 2021 Q1 | 127.4 Million SEK | 1.53% |
| 2021 Q3 | 149.4 Million SEK | 6.26% |
| 2021 Q2 | 140.6 Million SEK | 10.36% |
| 2020 Q3 | 141.5 Million SEK | -11.17% |
| 2020 FY | 125.48 Million SEK | -18.2% |
| 2020 Q1 | 155 Million SEK | 1.04% |
| 2020 Q2 | 159.3 Million SEK | 2.77% |
| 2020 Q4 | 125.48 Million SEK | -11.32% |
| 2019 Q3 | 154.3 Million SEK | 0.78% |
| 2019 FY | 153.4 Million SEK | 106.34% |
| 2019 Q1 | 144.6 Million SEK | 94.5% |
| 2019 Q2 | 153.1 Million SEK | 5.88% |
| 2019 Q4 | 153.4 Million SEK | -0.58% |
| 2018 Q2 | 56.3 Million SEK | -19.8% |
| 2018 Q4 | 74.34 Million SEK | 69.74% |
| 2018 FY | 74.34 Million SEK | 13.66% |
| 2018 Q1 | 70.2 Million SEK | 7.32% |
| 2018 Q3 | 43.8 Million SEK | -22.2% |
| 2017 Q1 | 61.2 Million SEK | 6.82% |
| 2017 Q4 | 65.41 Million SEK | 4.49% |
| 2017 Q3 | 62.6 Million SEK | -6.57% |
| 2017 Q2 | 67 Million SEK | 9.48% |
| 2017 FY | 65.41 Million SEK | 14.18% |
| 2016 Q2 | 18.3 Million SEK | -10.73% |
| 2016 FY | 57.29 Million SEK | -7.96% |
| 2016 Q4 | 57.29 Million SEK | 2.3% |
| 2016 Q3 | 56 Million SEK | 206.01% |
| 2016 Q1 | 20.5 Million SEK | -67.07% |
| 2015 Q2 | 53.8 Million SEK | 6.11% |
| 2015 Q4 | 62.24 Million SEK | 36.21% |
| 2015 Q3 | 45.7 Million SEK | -15.06% |
| 2015 Q1 | 50.7 Million SEK | -0.15% |
| 2015 FY | 62.24 Million SEK | 22.59% |
| 2014 FY | 50.77 Million SEK | 9.43% |
| 2014 Q2 | 47.7 Million SEK | 15.22% |
| 2014 Q4 | 50.77 Million SEK | -12.0% |
| 2014 Q3 | 57.7 Million SEK | 20.96% |
| 2014 Q1 | 41.4 Million SEK | -10.77% |
| 2013 Q2 | 39.36 Million SEK | 38.12% |
| 2013 Q1 | 28.5 Million SEK | 36.3% |
| 2013 FY | 46.39 Million SEK | 121.88% |
| 2013 Q4 | 46.39 Million SEK | -4.8% |
| 2013 Q3 | 48.74 Million SEK | 23.81% |
| 2012 Q2 | 12.94 Million SEK | 75.01% |
| 2012 Q3 | 5.89 Million SEK | -54.48% |
| 2012 Q4 | 20.91 Million SEK | 254.8% |
| 2012 FY | 20.91 Million SEK | -43.26% |
| 2012 Q1 | 7.39 Million SEK | -79.93% |
| 2011 Q1 | 38.96 Million SEK | 43.88% |
| 2011 Q4 | 36.85 Million SEK | -11.49% |
| 2011 Q3 | 41.64 Million SEK | -6.22% |
| 2011 Q2 | 44.4 Million SEK | 13.96% |
| 2011 FY | 36.85 Million SEK | 36.1% |
| 2010 Q4 | 27.08 Million SEK | 0.0% |
| 2010 FY | 27.08 Million SEK | 37.34% |
| 2009 FY | 19.71 Million SEK | -16.38% |
| 2008 FY | 23.58 Million SEK | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Acarix AB (publ) | - SEK | -Infinity% |
| ADDvise Group AB (publ) | 1.61 Billion SEK | 89.705% |
| ADDvise Group AB (publ) | 1.61 Billion SEK | 89.705% |
| Arcoma AB | 3.87 Million SEK | -4188.665% |
| Bactiguard Holding AB (publ) | 233.09 Million SEK | 28.743% |
| BICO Group AB (publ) | 1.85 Billion SEK | 91.037% |
| CellaVision AB (publ) | 64.7 Million SEK | -156.711% |
| Clinical Laserthermia Systems AB (publ) | 454 Thousand SEK | -36485.903% |
| Chordate Medical Holding AB (publ) | - SEK | -Infinity% |
| C-Rad AB (publ) | 1.8 Million SEK | -9127.778% |
| Duearity AB (publ) | 10.58 Million SEK | -1469.647% |
| Dignitana AB (publ) | 19.1 Million SEK | -769.451% |
| Episurf Medical AB (publ) | 5.2 Million SEK | -3094.231% |
| Getinge AB (publ) | 8.07 Billion SEK | 97.943% |
| Scandinavian Real Heart AB (Publ) | 8.24 Million SEK | -1913.425% |
| Iconovo AB (publ) | 7.72 Million SEK | -2050.187% |
| Integrum AB (publ) | 6.42 Million SEK | -2485.544% |
| Luxbright AB (publ) | 206.02 Thousand SEK | -80521.675% |
| Mentice AB (publ) | 9.55 Million SEK | -1637.993% |
| OssDsign AB (publ) | 3.15 Million SEK | -5173.016% |
| Paxman AB (publ) | 13.57 Million SEK | -1124.024% |
| Promimic AB (publ) | - SEK | -Infinity% |
| Qlife Holding AB (publ) | 20.73 Million SEK | -701.216% |
| SciBase Holding AB (publ) | 6.79 Million SEK | -2343.725% |
| ScandiDos AB (publ) | - SEK | -Infinity% |
| Sectra AB (publ) | 31.78 Million SEK | -422.524% |
| Sedana Medical AB (publ) | 4.3 Million SEK | -3757.408% |
| Senzime AB (publ) | 11.46 Million SEK | -1348.378% |
| SpectraCure AB (publ) | 6.71 Million SEK | -2372.83% |
| Stille AB | 62.94 Million SEK | -163.894% |
| Vitrolife AB (publ) | 2.08 Billion SEK | 92.049% |
| Xvivo Perfusion AB (publ) | 31.43 Million SEK | -428.358% |